NEW YORK (GenomeWeb) – Illumina said yesterday that it is providing high-density genotyping arrays at no charge to the National Institutes of Health's All of Us Research Program to process up to 1 million samples.
The biomedical research program plans to enroll at least 1 million participants in the US for health-related studies. Its precision medicine research platform will include genomic analyses by array-based genotyping and whole-genome sequencing. In September, the NIH awarded $28.6 million in funding to three genome centers that will generate the genomic data.
Illumina said the Infinium Global Diversity Array it will provide to the three genome centers "was developed for and inspired by" the All of Us program. It will enable "unparalleled coverage of a highly diverse cohort," as well as the return of key pharmacogenomic variants and results based on the American College of Medical Genetics and Genomics' ACMG-59 gene list to participants. The genome centers will also use Illumina's NovaSeq 6000 sequencing platform for the program, the company added.
The Infinium Global Diversity arrays will become commercially available for others to use in mid-2019.